Results 181 to 190 of about 147,441 (298)

Préface [de : On naît enfant]

open access: yes, 1985
Perret-Clermont, Anne-Nelly
core  

Management of retinopathy of prematurity in a tertiary referral neonatal intensive care unit: Treatment rates and the impact of outsourcing laser therapy

open access: yesActa Ophthalmologica, Volume 104, Issue 4, Page e416-e425, June 2026.
Abstract Purpose To describe the treatment rate for retinopathy of prematurity (ROP) at a tertiary referral neonatal intensive care unit (NICU) in the south‐western region of the Netherlands. In addition, we evaluated the impact of outsourcing laser treatment, implemented in 2018, by comparing treatment characteristics from 3 years prior and 3 years ...
L. A. Derks   +5 more
wiley   +1 more source

High frequency of CD95+/CD45RA− regulatory T cells defines an immunosuppressive profile associated with MDS progression

open access: yesBritish Journal of Haematology, Volume 208, Issue 6, Page 1993-2003, June 2026.
Summary Dynamic interactions between mutated haematopoietic cells and immune cells are key drivers of myelodysplastic neoplasms (MDS) initiation and progression. Regulatory T cells (Tregs) are central mediators of immunosuppression in MDS. We thus aimed to characterize Treg subpopulations in the bone marrow (BM) of MDS patients and to explore their ...
Romain Vazquez   +18 more
wiley   +1 more source

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin‐degrading enzyme, a new molecular vulnerability in multiple myeloma

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 12, Page 3355-3376, June 2026.
Inhibitors of insulin‐degrading enzyme boost PI cytotoxicity through an increased sensitivity of proteasome to PI inhibitors, induction of ISR, DNA damage and Myc down‐regulation. They overcome PI resistance in vitro and induce tumour regression in vivo.
Laetitia Lesire   +28 more
wiley   +1 more source

Three‐year outcomes of repeated botulinum neurotoxin A injections to the lower extremities in young children with spastic cerebral palsy in GMFCS levels I to III

open access: yesDevelopmental Medicine &Child Neurology, Volume 68, Issue 6, Page 792-799, June 2026.
In this study, we followed a group of children 2 to 6 years old with spastic cerebral palsy functioning in GMFCS levels I–III, over 3 years. Sixty‐five received BoNT‐A and 59 did not. Repeated BoNT‐A injections over 3 years were not associated with improvements in gross motor function or passive ankle dorsiflexion. Daily step counts, favouring the BoNT‐
Darcy Fehlings   +11 more
wiley   +1 more source

Intravenous immunoglobulin and febrile status epilepticus in children with Dravet syndrome: A retrospective multicentre study

open access: yesDevelopmental Medicine &Child Neurology, Volume 68, Issue 6, Page 857-863, June 2026.
This multicenter retrospective study evaluated the use of intravenous immunoglobulin (IVIG) in 14 children with Dravet syndrome as a preventive strategy against febrile status epilepticus. Over a 6‐month period, IVIG was associated with a significant reduction in hospitalizations for febrile status epilepticus.
Romane Marc   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy